Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 45 (Search time: 0.002 seconds).
previous
1
2
3
4
...
5
next
Item hits:
Preview
Issue Date
Title
Author(s)
2017
Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia
Sopper, S.
;
Mustjoki, S.
;
White, D.
;
Hughes, T.
;
Valent, P.
;
Burchert, A.
;
Gjertsen, B.
;
Gastl, G.
;
Baldauf, M.
;
Trajanoski, Z.
;
Giles, F.
;
Hochhaus, A.
;
Ernst, T.
;
Schenk, T.
;
Janssen, J.
;
Ossenkoppele, G.
;
Porkka, K.
;
Wolf, D.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2016
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Nievergall, E.
;
Reynolds, J.
;
Kok, C.
;
Watkins, D.
;
Biondo, M.
;
Busfield, S.
;
Vairo, G.
;
Fuller, K.
;
Erber, W.
;
Sadras, T.
;
Grose, R.
;
Yeung, D.
;
Lopez, A.
;
Hiwase, D.
;
Hughes, T.
;
White, D.
2016
Chronic myeloid leukemia: reminiscences and dreams
Mughal, T.
;
Radich, J.
;
Deininger, M.
;
Apperley, J.
;
Hughes, T.
;
Harrison, C.
;
Gambacorti-Passerini, C.
;
Saglio, G.
;
Cortes, J.
;
Daley, G.
2014
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
Eadie, L.
;
Hughes, T.
;
White, D.
2013
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients
Hughes, T.
;
White, D.
2014
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
Nievergall, E.
;
Ramshaw, H.
;
Yong, A.
;
Biondo, M.
;
Busfield, S.
;
Vairo, G.
;
Lopez, A.
;
Hughes, T.
;
White, D.
;
Hiwase, D.
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
Discover
Author
22
White, D.
11
Hochhaus, A.
10
Branford, S.
9
Kantarjian, H.
8
Saglio, G.
7
Kim, D.
7
Larson, R.
7
Radich, J.
7
Yeung, D.
6
Saunders, V.
.
next >
Subject
34
Pyrimidines
32
Leukemia, Myelogenous, Chronic, B...
28
Imatinib Mesylate
27
Piperazines
26
Benzamides
25
Antineoplastic Agents
24
Protein Kinase Inhibitors
16
Fusion Proteins, bcr-abl
14
Female
14
Male
.
next >
Date issued
2
2018
3
2017
2
2016
3
2014
12
2013
5
2012
7
2011
11
2010